

## **Anthony Ridgway, Ph.D.**

---

**USP Affiliation:** Member, Biologics and Biotechnology: Cell, Gene and Tissue Therapies Expert Committee

**Organization:** Health Canada  
Ottawa, Ontario

**Presentation:** Quality of Manufactured Medicines – Biology & Biotechnology  
*Process and Ancillary Materials*  
Wednesday, September 23, 2009; 10:30 a.m. to 12:30 p.m.

Dr. Ridgway was born and educated in the U.K. and completed his B.Sc. and Ph.D. in Biology at McGill University in Montréal. He proceeded to post-doctoral studies and then an Assistant Professorship in the Cancer Research Laboratory and Department of Microbiology and Immunology at the University of Western Ontario. Academic research activities included work on the structure and expression of oncogenes, retroviral regulatory elements, HIV regulatory genes, and inducible expression vectors.

He has been with Health Canada since 1991 and, in 1999, became manager of the Biotherapeutics Division, with responsibility for regulation of a wide range of products. In 2004 he guided the separation of his former division into three new divisions and assumed the new position of Senior Regulatory Scientist in the Office of the Director, in the newly formed Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics, where he holds a broad range of supervisory and advisory responsibilities. He has been active with the ICH\* since 1993, serving on Expert Working Groups addressing the quality of biotechnology products and, since its formation, on the Gene Therapy Discussion Group. Since June 2000, he has served on the US Pharmacopoeia Committee of Experts on Cell, Gene and Tissue Therapies.

(\*International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use)